In partnership with Qatar Biomedical Research Institute.
Since the emergence of the SARS-CoV-2 viral infection and related pandemic of COVID-19 disease in January 2020, biomedical researchers worldwide have refocused to meet the urgent demand for vaccine development, diagnosis for clinical and environmental samples, risk prediction for progression of COVID-19 to severe symptoms, and development of therapeutics and prophylactics. QBRI investigators responded to develop innovative diagnostics, strategies for repurposed therapeutics and prophylactics, with collaborators: Qatar University, Hamad Medical Corporation and WISH. Interim results from the World Health Organization Solidarity Therapeutics Trial indicate that treatments with remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon appear to have little or no effect on 28-day mortality or the in-hospital course of COVID-19 among hospitalized patients; so new treatment and prophylactic options are urgently required for COBVID-19. In this symposium, QBRI investigators at the frontline of the biomedical pushback against COVID-19 will present their insights and advances.